These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33847047)

  • 1. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
    Jering KS; Claggett B; Pfeffer MA; Granger C; Køber L; Lewis EF; Maggioni AP; Mann D; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; van der Meer P; Wernsing M; Carter K; Guo W; Zhou Y; Lefkowitz M; Gong J; Wang Y; Merkely B; Macin SM; Shah U; Nicolau JC; Braunwald E
    Eur J Heart Fail; 2021 Jun; 23(6):1040-1048. PubMed ID: 33847047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
    Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
    Mann DL; Nicolas J; Claggett B; Miao ZM; Granger CB; Kerkar P; Køber L; Lewis EF; McMurray JJV; Maggioni AP; Núñez J; Ntsekhe M; Rouleau JL; Sim D; Solomon SD; Steg PG; van der Meer P; Braunwald E; Pfeffer MA; Mehran R
    J Am Coll Cardiol; 2024 Mar; 83(9):904-914. PubMed ID: 38418004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
    Schou M; Claggett B; Miao ZM; Fernandez A; Filippatos G; Granger C; Jering K; Maggioni AP; McCausland F; Villota JN; Rouleau JL; Mody FV; van der Meer P; Vinereanu D; McGrath M; Zhou Y; Mann DL; Solomon SD; Steg PG; Braunwald E; McMurray JJV; Pfeffer MA; Køber L
    Eur J Heart Fail; 2024 Jan; 26(1):130-139. PubMed ID: 37933184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; East C; Fernandez A; Jering K; Landmesser U; Mehran R; Merkely B; Vaghaiwalla Mody F; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Gong J; Braunwald E;
    N Engl J Med; 2021 Nov; 385(20):1845-1855. PubMed ID: 34758252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics'.
    El-Battrawy I; Akin I
    Eur J Heart Fail; 2022 Jul; 24(7):1324. PubMed ID: 35118775
    [No Abstract]   [Full Text] [Related]  

  • 9. Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.
    Curtain JP; Pfeffer MA; Braunwald E; Claggett BL; Granger CB; Køber L; Lewis EF; Maggioni AP; Mann DL; Rouleau JL; Solomon SD; Steg PG; Finn PV; Fernandez A; Jering KS; McMurray JJV
    JAMA Cardiol; 2024 Oct; 9(10):928-933. PubMed ID: 39110471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
    Berwanger O; Pfeffer M; Claggett B; Jering KS; Maggioni AP; Steg PG; Mehran R; Lewis EF; Zhou Y; van der Meer P; De Pasquale C; Merkely B; Filippatos G; McMurray JJV; Granger CB; Solomon SD; Braunwald E
    Eur J Heart Fail; 2022 Oct; 24(10):1918-1927. PubMed ID: 36054480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
    Rezq A; Saad M; El Nozahi M
    Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
    Jering KS; Claggett BL; Pfeffer MA; Granger CB; Køber L; Lewis EF; Maggioni AP; Mann DL; McMurray JJV; Prescott MF; Rouleau JL; Solomon SD; Steg PG; von Lewinski D; Braunwald E
    Circ Heart Fail; 2023 May; 16(5):e010259. PubMed ID: 37125529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.
    Yin H; Ma L; Zhou Y; Tang X; Li R; Zhou Y; Shi J; Zhang J
    Heart Vessels; 2024 Aug; 39(8):673-686. PubMed ID: 38635062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiotensine Receptor-Neprilysin Inhibitor combination is not the preferred medication for patients after acute myocardial infarction].
    Kok W
    Ned Tijdschr Geneeskd; 2022 May; 166():. PubMed ID: 35736368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
    Pathak P
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Gu J; Wang Y; Wang CQ; Zhang JF
    Eur J Intern Med; 2023 Jun; 112():62-69. PubMed ID: 36990878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.